Navigation Links
Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
Date:12/9/2008

TSX: BMR

TORONTO, Dec. 9 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer will be presenting as a panel participant at the 2008 RBC Capital Markets Healthcare Conference, held at the Westin Times Square Hotel in New York City. The panel titled, Antibody Strategies For Fighting Cancer, is scheduled from 3:30 pm to 4:25 pm (Eastern Time) on December 10, 2008 in Panel Room 2. Interested parties can access a live audio webcast of the panel by visiting Bradmer's website at www.bradmerpharma.com. The webcast will be available for 30 days after the conference.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab(R), was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bradmer announces management changes
2. Bradmer provides Phase III Neuradiab trial update and guidance
3. Bradmer to present at Rodman & Renshaw Healthcare Conference
4. Bradmer Medical Isotope Supply For Phase III Trial Secure
5. Bradmer announces additions to Scientific Advisory Board
6. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
7. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
10. Bradmer announces new additions to management team
11. Bradmer announces 2008 first quarter operational and financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of year ... Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian cancer ... Cundiff. , “We are honored to support a promising young investigator from Dr. Lengyel’s ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... World Molecular Imaging Congress (WMIC), will be held in New York City, NY ... “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals a ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Early this week, ... and raise awareness of Nestlé KITKAT as the first global confectionery brand sourced from ... cocoa farmers and the quality of their product, through activities that focus on better ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... Walton Beach, Florida (PRWEB) , ... February 10, ... ... the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at the ... platform, MetLoop has “put the power of the world's most advanced weather technology ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , February 10, 2016 ... Analyzers (Liquid & Gas), and Spectroscopy Market by Industry (Oil ... Beverage, Pulp & Paper, Metal & Mining, and Others), ... MarketsandMarkets, the global market is expected to grow to ... of 8.6% between 2015 and 2020. Browse ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
Breaking Medicine Technology: